ONO4057 (ONO-LB457)
(Synonyms: ONO-LB457) 目录号 : GC32011
ONO4057 (ONO-LB457) 是一种白三烯 B4 受体拮抗剂，IC50 为 0.&7#177;0.3 μM。
Cas No.:134578-96-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ONO4057 is a Leukotriene B4 receptor antagonist, with an IC50 of 0.7±0.3 μM.
Mean animal survivals of the ONO4057-treated animals significantly prolong to 21.0±4.4 days compare with 12.0±0.6 days in control group. Histological findings from grafts taken on day 7 show that severe focal cellular infiltration is observed in both groups, but the degree of hepatocyte necrosis in ONO4057-treated anmimals is milder than that in control group[2].
[1]. Kishikawa K, et al. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins. 1992 Oct;44(4):261-75. [2]. Tanaka M, et al. Effect of leukotriene B(4) receptor antagonist (ONO4057) on hepatic allografting in rats. Transplant Proc. 2000 Nov;32(7):2340.
Animal experiment: | Inbred male ACI (180 to 210 g) and LEW (200 to 240 g) rats are used as donors and recipients. Liver transplantation is orthotopically performed. ONO4057 dissolved in 7% NaHCO3 or solvent is administered subcutaneously daily after transplantation. Animals are divided into two groups: group I (n=5), 7% NaHCO3 3 mL/kg as controls; group II (n=6), ONO4057 30 mg/kg per day[2]. |
References: [1]. Kishikawa K, et al. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins. 1992 Oct;44(4):261-75. | |
| Cas No. | 134578-96-4 | SDF | |
| 别名 | ONO-LB457 | ||
| Canonical SMILES | O=C(O)CCC1=C(OCCCC/C=C/C2=CC=C(OC)C=C2)C=CC=C1OCCCCC(O)=O | ||
| 分子式 | C27H34O7 | 分子量 | 470.55 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1252 mL | 10.6259 mL | 21.2517 mL |
| 5 mM | 0.425 mL | 2.1252 mL | 4.2503 mL |
| 10 mM | 0.2125 mL | 1.0626 mL | 2.1252 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet